Gastroenterology
Volume 135, Issue 3 , Pages 787-795 , September 2008

Safety and Immunogenicity of an Intramuscular Helicobacter pylori Vaccine in Noninfected Volunteers: A Phase I Study

  • Peter Malfertheiner

      Affiliations

    • Otto-von-Guericke Universitaet, Department of Gastroenterology, Hepatology and Infectious Diseases, Magdeburg, Germany
    • ,
  • Viola Schultze

      Affiliations

    • Novartis Vaccines, Marburg, Germany
    • ,
  • Bernd Rosenkranz

      Affiliations

    • Clinical Research, Universitaetsklinikum Charité, Berlin, Germany
    • ,
  • Stefan H.E. Kaufmann

      Affiliations

    • Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany
    • ,
  • Timo Ulrichs

      Affiliations

    • Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany
    • ,
  • Deborah Novicki

      Affiliations

    • Novartis Vaccines, Emeryville, California
    • ,
  • Francesco Norelli

      Affiliations

    • Novartis Vaccines, Siena, Italy
    • ,
  • Mario Contorni

      Affiliations

    • Novartis Vaccines, Siena, Italy
    • ,
  • Samuele Peppoloni

      Affiliations

    • Novartis Vaccines, Siena, Italy
    • ,
  • Duccio Berti

      Affiliations

    • Novartis Vaccines, Siena, Italy
    • ,
  • Daniela Tornese

      Affiliations

    • Novartis Vaccines, Siena, Italy
    • ,
  • Jitendra Ganju

      Affiliations

    • Novartis Vaccines, Emeryville, California
    • ,
  • Emanuela Palla

      Affiliations

    • Novartis Vaccines, Siena, Italy
    • ,
  • Rino Rappuoli

      Affiliations

    • Novartis Vaccines, Siena, Italy
    • ,
  • Bruce F. Scharschmidt

      Affiliations

    • Novartis Vaccines, Emeryville, California
    • ,
  • Giuseppe Del Giudice

      Affiliations

    • Novartis Vaccines, Siena, Italy
    • Corresponding Author InformationAddress requests for reprints to: Giuseppe Del Giudice, MD, Novartis Vaccines, Research Center, Via Fiorentina 1, 53100 Siena, Italy. fax: +39-0577-243564

Received 6 September 2007 ,Accepted 21 May 2008.

References 

  1. Covacci A, Telford J, Del Giudice G, et al. Helicobacter pylori, virulence and genetic geography. Science. 1999;284:1328–1333
  2. Graham DY, Malaty HM, Evans DG, et al. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States (Effect of age, race, and socioeconomic status). Gastroenterology. 1991;100:1595–1601
  3. Frenck RW, Clemens J. Helicobacter in the developing world. Microbes Infect. 2003;5:705–713
  4. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347:1175–1186
  5. Parsonnet J, Friedman G, Vandersteen D, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325:1127–1131
  6. Parsonnet J, Hansen S, Rodriguez L, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med. 1994;330:1267–1271
  7. Collins J, Ali-Ibrahim A, Smoot DT. Antibiotic therapy for Helicobacter pylori. Med Clin North Am. 2006;1125–1140
  8. Gerrits MM, van Vliet AH, Kuipers EJ, et al. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. Lancet Inf Dis. 2007;11:699–709
  9. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection—The Maastricht III Consensus Report. Gut. 2007;56:772–781
  10. Parsonnet J. What is the Helicobacter pylori global reinfection rate?. Can J Gastroenterol. 2003;17(Suppl B):46B–48B
  11. Institute of Medicine. Vaccines for the 21st century: a tool for decision making. In:  Stratton KR,  Durch JS,  Lawrence RS editor. Washington DC: National Academy Press; 2001;p. 181–188
  12. Rupnow MFT, Owens DK, Shachter R. Helicobacter pylori vaccine development and use: a cost-effectiveness analysis using the Institute of Medicine Methodology. Helicobacter. 1999;4:272–280
  13. Rupnow MF, Shachter RD, Owens DK, et al. Quantifying the population impact of a prophylactic Helicobacter pylori vaccine. Vaccine. 2001;20:879–885
  14. Del Giudice G, Covacci A, Telford J, et al. The design of vaccines against Helicobacter pylori and their development. Annu Rev Immunol. 2001;19:523–563
  15. Del Giudice G, Michetti P. Inflammation, immunity and vaccines for Helicobacter pylori. Helicobacter. 2004;9(suppl 1):23–28
  16. Montecucco C, Rappuoli R. Living dangerously: how Helicobacter pylori survives in the human stomach. Nature Rev Mol Cell Biol. 2001;2:457–466
  17. Michetti P, Kreiss C, Kotloff KL, et al. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology. 1999;116:804–812
  18. Banerjee S, Medina-Fatimi A, Nichols R, et al. Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease base oral immunisation against Helicobacter pylori in healthy volunteers. Gut. 2002;51:634–640
  19. Sougioultzis S, Lee CK, Alsahli M, et al. Safety and efficacy of E. coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori. Vaccine. 2002;21:194–201
  20. DiPetrillo MD, Tibbetts T, Kleanthous H, et al. Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine. 2000;18:449–459
  21. Angelakopoulos H, Hohmann EL. Pilot study of phoP/phoQ-deleted Salmonella enterica serovar Typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect Immun. 2000;68:2135–2141
  22. Bumann D, Metzger WG, Mansouri E, et al. Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21a expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine. 2002;20:845–852
  23. Metzger WG, Mansouri E, Kronawitter M, et al. Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar Typhi Ty21a vaccine expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine. 2004;22:2273–2277
  24. De Bernard M, Cappon A, Del Giudice G, et al. The multiple cellular activities of the VacA cytotoxin of Helicobacter pylori. Int J Med Microbiol. 2004;293:589–597
  25. Censini S, Lange C, Xiang Z, et al. Cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci U S A. 1996;93:14648–14653
  26. Odenbreit S, Puls J, Sedlmaier B, et al. Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion. Science. 2000;287:1497–1500
  27. Stein M, Rappuoli R, Covacci A. Tyrosine phosphorylation of the Helicobacter pylori CagA antigen after cag-driven host cell translocation. Proc Natl Acad Sci U S A. 2000;97:1263–1268
  28. Dundon WG, Nishioka H, Polenghi A, et al. The neutrophil-activating protein of Helicobacter pylori. Int J Med Microbiol. 2002;29:545–550
  29. Amedei A, Cappon A, Codolo G, et al. The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. J Clin Invest. 2006;116:1092–1101
  30. Marchetti M, Arico B, Burroni D, et al. Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science. 1995;267:1655–1658
  31. Marchetti M, Rossi M, Giannelli V, et al. Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant. Vaccine. 1998;16:33–37
  32. Satin B, Del Giudice G, Della Bianca S, et al. The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor. J Exp Med. 2000;191:1567–1576
  33. Rossi G, Rossi M, Vitali CG, et al. A conventional Beagle dog model for acute and chronic infection with Helicobacter pylori. Infect Immun. 1999;67:3112–3120
  34. Rossi G, Fortuna D, Pancotto L, et al. Immunohistochemical study of lymphocyte populations infiltrating the gastric mucosa of Beagle dogs experimentally infected with Helicobacter pylori. Infect Immun. 2000;68:4769–4772
  35. Rossi G, Ruggiero P, Peppoloni S, et al. Therapeutic vaccination against Helicobacter pylori in the beagle dog experimental model: safety, immunogenicity, and efficacy. Infect Immun. 2004;72:3252–3259
  36. Gottwein JM, Blanchard TG, Targoni OS, et al. Protective anti-Helicobacter immunity is induced with aluminium hydroxide or complete Freund's adjuvant by systemic immunization. J Infect Dis. 2001;184:308–314
  37. Eisenberg JC, Czinn SJ, Garhart CA, et al. Protective efficacy of anti-Helicobacter pylori immunity following systemic immunization of neonatal mice. Infect Immun. 2003;71:1820–1827
  38. Covacci A, Censini S, Bugnoli M, et al. Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc Natl Acad Sci U S A. 1993;90:5791–5795
  39. Manetti R, Massari P, Burroni D, et al. Helicobacter pylori cytotoxin: importance of native conformation for induction of neutralizing antibodies. Infect Immun. 1995;63:4476–4480
  40. Vogel FR, Hem SL. Immunologic adjuvants. In:  Plotkin SA,  Orenstein WA editor. Vaccines. 4th ed.. Philadelphia: Saunders; 2004;p. 69–79
  41. Kotloff KL, Sztein MB, Wassermann SS, et al. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect Immun. 2001;69:3581–3590
  42. Tonello F, Dundon WG, Satin B, et al. The Helicobacter pylori neutrophil activating protein is an iron binding protein with dodecameric structure. Mol Microbiol. 1999;34:238–246
  43. Zanotti G, Papinutto E, Dundon WG, et al. Structure of the neutrophil-activating protein from Helicobacter pylori. J Mol Biol. 2002;323:125–130
  44. De Rosa SC, Lu FX, Yu J, et al. Vaccination in humans generates broad T cell cytokine responses. J Immunol. 2004;173:5372–5380
  45. Ernst PB, Peura DA, Crowe SE. The translation of Helicobacter pylori basic research to patient care. Gastroenterology. 2006;130:188–206
  46. Crowcroft NS, Pebody RG. Recent developments in pertussis. Lancet. 2006;367:1926–1936
  47. Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest. 2006;116:1167–1173

 Sponsored by Chiron Corporation (now Novartis Vaccines). P. Malfertheiner, S.H.E. Kaufmann, and T. Ulrichs have no financial interest in the product and have no other conflicting interests. B. Rosenkranz was employee of the phase I unit and CRO. At the time of the study V. Schultze, D. Novicki, F. Norelli, M. Contorni, D. Berti, S. Peppoloni, D. Tornese, J. Ganju, E. Palla, R. Rappuoli, B.F. Scharschmidt, and G. Del Giudice were employees of Chiron Corporation (now Novartis Vaccines).

PII: S0016-5085(08)00902-5

doi: 10.1053/j.gastro.2008.05.054

Gastroenterology
Volume 135, Issue 3 , Pages 787-795 , September 2008

Article Tools

* Image Usage & Resolution